Central neurocytoma: two case reports and review of the literature

Tommasi, Antonio De; D’Urso, Pietro Ivo; Tommasi, Claudio De; Sanguedolce, Francesca; Cimmino, Antonietta; Ciappetta, Pasqualino

doi:10.1007/s10143-006-0041-9

Cited by 19 publications

(20 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CNs mostly affect young adults between 20 and 40 years of age, with a peak at 30 years of age ( Fig. 1) [9]. We have observed that both genders can be equally affected, which are consistent with previous reports [14,49].…”

Section: Incidencesupporting

confidence: 88%

Surgical management of intraventricular central neurocytoma: 92 cases

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Incidencesupporting

confidence: 88%

Surgical management of intraventricular central neurocytoma: 92 cases

et al. 2012

View full text Add to dashboard Cite

show abstract

“…CN comprise 0.1-0.5% of all intracranial tumors, with only a limited number of cases reported since they were recognized as a separate pathological entity by Hassoun et al [1] in 1982 [18,19] . CN resemble oligodendrogliomas because of their appearance under light microscopy; either special staining for synaptophysin or neuron-specific enolase, or electron microscopy for neuronal ultrastructural features is required to make the diagnosis [20,21] .…”

Section: Discussionmentioning

confidence: 99%

Gamma Knife Radiosurgery for Central Neurocytoma: Retrospective Analysis of Fourteen Cases with a Median Follow-Up Period of Sixty-Five Months

Chen

Pan²,

Chung³

et al. 2011

Stereotact Funct Neurosurg

View full text Add to dashboard Cite

Object: Central neurocytoma (CN) is considered to be a benign neuronal tumor with possible atypical behavior. Microsurgery, radiation therapy (RT) and radiosurgery all have been used in treating this rare disease during the past decade. In this study, the authors present the experience with gamma knife radiosurgery (GKRS) on 14 patients with CN during a median follow-up period of 65 months and document the safety and efficacy of GKRS in the treatment of CN. Methods: Between November 1997 and December 2009, 14 patients pathologically diagnosed with CN were treated with GKRS. Follow-up magnetic resonance imaging (MRI) was performed at 6-month intervals. Tumor volume and adverse radiation effects (ARE) were documented to evaluate tumor response to GKRS. The Karnofsky Performance Scale (KPS) and neurological status were used to assess clinical outcome. The mean radiation dose prescribed to the tumor margin was 12.1 Gy (ranging from 11 to 13 Gy). The mean tumor volume was 19.6 ml (ranging from 3.5 to 48.9 ml). The mean follow-up period was 70 months (ranging from 30 to 140 months), and the median follow-up period was 65 months. Results: Tumor shrinkage was found in all patients at the final MRI follow-up. The mean volume reduction was 69% (ranging from 47 to 87%). No tumor progression, ARE or radiation-related toxicity developed in any of the cases. The KPS scores of all patients were the same or had increased, and the neurological functions were all stable without deterioration at the final follow-up. Conclusion: In our observations, GKRS was found to be an effective and safe alternative as adjuvant therapy for pathology-confirmed CN. The tumor volume and functional outcome can be controlled with a favorable result in long-term observation. Compared with RT and microsurgery, GKRS plays an important role in the treatment of CN as a minimally invasive technique with low morbidity. Regular long-term MRI follow-up should be mandatory to document the tumor response and possible recurrence. Multicenter consortia should be considered for further investigation and evaluation of GKRS for such a rare tumor.

show abstract

“…There was not any mitotic activity, necrosis, pleomorphism, microvascular proliferation ( Figure 3). with in a fibrillary stroma, mimicking a neuropil [1][2][3][4]. Chromatin has usually a salt and pepper appearance.…”

Section: Image Articlementioning

confidence: 99%

“…A few cells, which probably representing entrapped astrocytic glial cells, show staining for glial fibrillary acid protein (GFAP). A typical neurocytoma is a rare variant of CN, with cellular pleomorphism, miCentral neurocytomas (CNs) are extremely rare tumors mainly seen in the 20-40 year age group with a pre dominant location in the lateral ventricles near Monro for amina, in the septum pellucidum or on the ventricle walls representing not more than 0.5%-0.7% of all intra cranial tumors [2,3]. Less than 500 cases of CNs have been described including large series [2,3] since there cognition of CNs as a separate pathological entity in 1982 [4].…”

Section: Image Articlementioning

confidence: 99%

“…CNs is believed to originate from progenitor bipotential (neuronal and astrocytic) cells which persist into adulthood in the periventricular region. In order to achieve a right diagnosis, a tumour biopsy is always necessary and to establish a risk of tumour recurrence or progression as well as to aid to classify the patients in high or low-risk groups [2]. Gross total tumour removal is the treatment of choice because of high rate of local control and survival [1][2][3][4].…”

Section: Image Articlementioning

confidence: 99%

See 1 more Smart Citation